WEKO3
アイテム
{"_buckets": {"deposit": "e40cba36-28e6-481b-94d0-1982fe9c4a38"}, "_deposit": {"created_by": 11, "id": "3946", "owners": [11], "pid": {"revision_id": 0, "type": "depid", "value": "3946"}, "status": "published"}, "_oai": {"id": "oai:shiga-med.repo.nii.ac.jp:00003946", "sets": ["37"]}, "author_link": [], "item_6_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2019-09", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "5", "bibliographicVolumeNumber": "30", "bibliographic_titles": [{"bibliographic_title": "Journal of J Gynecologic Oncology", "bibliographic_titleLang": "en"}]}]}, "item_6_creator_3": {"attribute_name": "著者別名", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "米岡, 完", "creatorNameLang": "ja"}]}]}, "item_6_date_granted_70": {"attribute_name": "学位授与年月日", "attribute_value_mlt": [{"subitem_dategranted": "2021-03-09"}]}, "item_6_degree_grantor_68": {"attribute_name": "学位授与機関", "attribute_value_mlt": [{"subitem_degreegrantor": [{"subitem_degreegrantor_language": "ja", "subitem_degreegrantor_name": "滋賀医科大学"}], "subitem_degreegrantor_identifier": [{"subitem_degreegrantor_identifier_name": "14202", "subitem_degreegrantor_identifier_scheme": "kakenhi"}]}]}, "item_6_degree_name_67": {"attribute_name": "学位名", "attribute_value_mlt": [{"subitem_degreename": "博士(医学)", "subitem_degreename_language": "ja"}]}, "item_6_description_14": {"attribute_name": "フォーマット", "attribute_value_mlt": [{"subitem_description": "pdf", "subitem_description_type": "Other"}]}, "item_6_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Objective:\nTo treat advanced ovarian cancer, interval debulking surgery (IDS) is performed after 3 cycles each of neoadjuvant chemotherapy (NAC) and postoperative chemotherapy (IDS group). If we expect that complete resection cannot be achieved by IDS, debulking surgery is performed after administering additional 3 cycles of chemotherapy without postoperative chemotherapy (Add-C group). We evaluated the survival outcomes of the Add-C group and determined their serum cancer antigen 125 (CA125) levels to predict complete surgery. ", "subitem_description_language": "en", "subitem_description_type": "Abstract"}, {"subitem_description": "Methods:\nA retrospective chart review of all stage III and IV ovarian, fallopian tube, and peritoneal cancer patients treated with NAC in 2007-2016 was conducted. ", "subitem_description_language": "en", "subitem_description_type": "Abstract"}, {"subitem_description": "Results:\nAbout 117 patients comprised the IDS group and 26 comprised the Add-C group. Univariate and multivariate analyses revealed that Add-C group had an equivalent effect on progression-free survival (PFS; p=0.09) and overall survival (OS; p=0.94) compared with the IDS group. Multivariate analysis revealed that patients who developed residual disease after surgery had worse PFS (hazard ratio [HR]=2.18; 95% confidence interval [CI]=1.45-3.28) and OS (HR=2.33; 95% CI=1.43-3.79), and those who received \u003c6 cycles of chemotherapy had worse PFS (HR=5.30; 95% CI=2.56-10.99) and OS (HR=3.05; 95% CI=1.46-6.38). The preoperative serum CA125 cutoff level was 30 U/mL based on Youden index method. ", "subitem_description_language": "en", "subitem_description_type": "Abstract"}, {"subitem_description": "Conclusions:\nAdministering 3 additional cycles of chemotherapy followed by debulking surgery exhibited equivalent effects on survival as IDS followed by 3 cycles of postoperative chemotherapy. Preoperative serum CA125 levels of ≤30 U/mL may be a useful predictor of achieving complete surgery. ", "subitem_description_language": "en", "subitem_description_type": "Abstract"}]}, "item_6_description_42": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"subitem_description": "Thesis or Dissertation", "subitem_description_type": "Other"}]}, "item_6_description_69": {"attribute_name": "学位授与年度", "attribute_value_mlt": [{"subitem_description": "令和2年度", "subitem_description_language": "ja", "subitem_description_type": "Other"}]}, "item_6_dissertation_number_71": {"attribute_name": "学位授与番号", "attribute_value_mlt": [{"subitem_dissertationnumber": "乙第455号"}]}, "item_6_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Asian Society of Gynecologic Oncology", "subitem_publisher_language": "en"}]}, "item_6_relation_10": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "31328461", "subitem_relation_type_select": "PMID"}}]}, "item_6_relation_11": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "10.3802/jgo.2019.30.e81"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.3802/jgo.2019.30.e81", "subitem_relation_type_select": "DOI"}}]}, "item_6_relation_48": {"attribute_name": "関係URI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "博士論文要旨"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "http://hdl.handle.net/10422/00013005", "subitem_relation_type_select": "HDL"}}]}, "item_6_rights_12": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "© 2019. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology. "}]}, "item_6_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "2005-0399 ", "subitem_source_identifier_type": "EISSN"}]}, "item_6_version_type_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "open access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_abf2"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "YONEOKA, Yutaka", "creatorNameLang": "en"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2021-07-14"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "jgo.2019.30.e81.pdf", "filesize": [{"value": "1.3 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensefree": "This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.", "licensetype": "license_note", "mimetype": "application/pdf", "size": 1300000.0, "url": {"label": "jgo.2019.30.e81", "objectType": "fulltext", "url": "https://shiga-med.repo.nii.ac.jp/record/3946/files/jgo.2019.30.e81.pdf"}, "version_id": "7b42116f-e490-4f2c-949f-c4ed3c012157"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "CA-125 Antigen", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Cytoreduction Surgical Procedures", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Neoadjuvant Therapy", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Ovarian Neoplasm", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "doctoral thesis", "resourceuri": "http://purl.org/coar/resource_type/c_db06"}]}, "item_title": "Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy?", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy?", "subitem_title_language": "en"}]}, "item_type_id": "6", "owner": "11", "path": ["37"], "permalink_uri": "http://hdl.handle.net/10422/00013044", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2021-07-14"}, "publish_date": "2021-07-14", "publish_status": "0", "recid": "3946", "relation": {}, "relation_version_is_last": true, "title": ["Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy?"], "weko_shared_id": -1}
Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy?
http://hdl.handle.net/10422/00013044
http://hdl.handle.net/10422/000130445f6d4eab-9715-4140-b60e-9dc7a23c5f55
名前 / ファイル | ライセンス | アクション |
---|---|---|
jgo.2019.30.e81 (1.3 MB)
|
|
Item type | 学位論文 / Thesis or Dissertation(1) | |||||||
---|---|---|---|---|---|---|---|---|
公開日 | 2021-07-14 | |||||||
タイトル | ||||||||
言語 | en | |||||||
タイトル | Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy? | |||||||
言語 | ||||||||
言語 | eng | |||||||
キーワード | ||||||||
言語 | en | |||||||
主題Scheme | Other | |||||||
主題 | CA-125 Antigen | |||||||
キーワード | ||||||||
言語 | en | |||||||
主題Scheme | Other | |||||||
主題 | Cytoreduction Surgical Procedures | |||||||
キーワード | ||||||||
言語 | en | |||||||
主題Scheme | Other | |||||||
主題 | Neoadjuvant Therapy | |||||||
キーワード | ||||||||
言語 | en | |||||||
主題Scheme | Other | |||||||
主題 | Ovarian Neoplasm | |||||||
資源タイプ | ||||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_db06 | |||||||
資源タイプ | doctoral thesis | |||||||
アクセス権 | ||||||||
アクセス権 | open access | |||||||
アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||||
著者 |
YONEOKA, Yutaka
× YONEOKA, Yutaka
|
|||||||
著者別名 |
米岡, 完
× 米岡, 完
|
|||||||
抄録 | ||||||||
内容記述タイプ | Abstract | |||||||
内容記述 | Objective: To treat advanced ovarian cancer, interval debulking surgery (IDS) is performed after 3 cycles each of neoadjuvant chemotherapy (NAC) and postoperative chemotherapy (IDS group). If we expect that complete resection cannot be achieved by IDS, debulking surgery is performed after administering additional 3 cycles of chemotherapy without postoperative chemotherapy (Add-C group). We evaluated the survival outcomes of the Add-C group and determined their serum cancer antigen 125 (CA125) levels to predict complete surgery. |
|||||||
言語 | en | |||||||
抄録 | ||||||||
内容記述タイプ | Abstract | |||||||
内容記述 | Methods: A retrospective chart review of all stage III and IV ovarian, fallopian tube, and peritoneal cancer patients treated with NAC in 2007-2016 was conducted. |
|||||||
言語 | en | |||||||
抄録 | ||||||||
内容記述タイプ | Abstract | |||||||
内容記述 | Results: About 117 patients comprised the IDS group and 26 comprised the Add-C group. Univariate and multivariate analyses revealed that Add-C group had an equivalent effect on progression-free survival (PFS; p=0.09) and overall survival (OS; p=0.94) compared with the IDS group. Multivariate analysis revealed that patients who developed residual disease after surgery had worse PFS (hazard ratio [HR]=2.18; 95% confidence interval [CI]=1.45-3.28) and OS (HR=2.33; 95% CI=1.43-3.79), and those who received <6 cycles of chemotherapy had worse PFS (HR=5.30; 95% CI=2.56-10.99) and OS (HR=3.05; 95% CI=1.46-6.38). The preoperative serum CA125 cutoff level was 30 U/mL based on Youden index method. |
|||||||
言語 | en | |||||||
抄録 | ||||||||
内容記述タイプ | Abstract | |||||||
内容記述 | Conclusions: Administering 3 additional cycles of chemotherapy followed by debulking surgery exhibited equivalent effects on survival as IDS followed by 3 cycles of postoperative chemotherapy. Preoperative serum CA125 levels of ≤30 U/mL may be a useful predictor of achieving complete surgery. |
|||||||
言語 | en | |||||||
学位名 | ||||||||
言語 | ja | |||||||
学位名 | 博士(医学) | |||||||
学位授与機関 | ||||||||
学位授与機関識別子Scheme | kakenhi | |||||||
学位授与機関識別子 | 14202 | |||||||
言語 | ja | |||||||
学位授与機関名 | 滋賀医科大学 | |||||||
学位授与年度 | ||||||||
内容記述タイプ | Other | |||||||
内容記述 | 令和2年度 | |||||||
言語 | ja | |||||||
学位授与年月日 | ||||||||
学位授与年月日 | 2021-03-09 | |||||||
学位授与番号 | ||||||||
学位授与番号 | 乙第455号 | |||||||
書誌情報 |
en : Journal of J Gynecologic Oncology 巻 30, 号 5, 発行日 2019-09 |
|||||||
出版者 | ||||||||
言語 | en | |||||||
出版者 | Asian Society of Gynecologic Oncology | |||||||
権利 | ||||||||
権利情報 | © 2019. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology. | |||||||
フォーマット | ||||||||
内容記述タイプ | Other | |||||||
内容記述 | ||||||||
著者版フラグ | ||||||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||||
ISSN | ||||||||
収録物識別子タイプ | EISSN | |||||||
収録物識別子 | 2005-0399 | |||||||
PMID | ||||||||
識別子タイプ | PMID | |||||||
関連識別子 | 31328461 | |||||||
DOI | ||||||||
識別子タイプ | DOI | |||||||
関連識別子 | https://doi.org/10.3802/jgo.2019.30.e81 | |||||||
関連名称 | 10.3802/jgo.2019.30.e81 | |||||||
資源タイプ | ||||||||
内容記述タイプ | Other | |||||||
内容記述 | Thesis or Dissertation | |||||||
関係URI | ||||||||
識別子タイプ | HDL | |||||||
関連識別子 | http://hdl.handle.net/10422/00013005 | |||||||
関連名称 | 博士論文要旨 |